Use of nadolol to treat chronic obstructive pulmonary disease by blockage of the arrestin-2 pathway
AssigneeChronic Airway Therapeutics Limited
InventorMitchell Glass
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compositions and methods for treating chronic obstructive pulmonary disease (COPD) and other diseases and conditions affecting the respiratory tract through inhibition of the β-arrestin (arrestin-2) pathway by use of β-adrenergic inverse agonists, particularly including nadolol. The compositions and methods can be used to treat pulmonary symptoms associated with infection with SARS-CoV-2.
Claims23
-168. (canceled)
A method for treatment of pulmonary airway disease in a subject suffering from pulmonary airway disease comprising administration of a therapeutically effective quantity of nadolol to inhibit the R-arrestin pathway to treat the pulmonary airway disease in the subject.
A pharmaceutical composition comprising:
- (a) a therapeutically effective quantity of nadolol to inhibit the R-arrestin pathway to treat a pulmonary airway disease;
- and
- (b) a pharmaceutically acceptable carrier;
- wherein administration of the pharmaceutical composition treats the pulmonary airway disease.
Dependencies are inferred from the claim text.